APA (7th ed.) Citation

RC, S., RE, L., H, H., DP, W., S, R. M., J, S., . . . SN, G. (2025). Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study. The Journal of clinical psychiatry, 86(3), . https://doi.org/10.4088/JCP.23m15246

Chicago Style (17th ed.) Citation

RC, Shelton, et al. "Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study." The Journal of Clinical Psychiatry 86, no. 3 (2025). https://doi.org/10.4088/JCP.23m15246.

MLA (9th ed.) Citation

RC, Shelton, et al. "Rapid Onset and Sustained Efficacy of Onfasprodil (MIJ821), a Novel NR2B Negative Allosteric Modulator, in Patients With Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study." The Journal of Clinical Psychiatry, vol. 86, no. 3, 2025, https://doi.org/10.4088/JCP.23m15246.